Outreach Signals
Publishing Details
About This Podcast
We are a medical communications company with a passion for developing high-quality content. We write & design content for healthcare professionals and patients in a variety of therapeutic areas. If you like our podcast, please take the time to rate it and subscribe. See our website for more information, video capsules, and podcasts at: https://www.impactmedicom.com.
Explore Statistics
Recent Episodes
Introduction to the Canadian Hematology Consensus Group (CHCG)
Dr. Carolyn Owen, Chair of the Canadian Hematology Consensus Group (CHCG), introduces the CHCG and discusses its mission to develop evidence-based Canadian consensus recommendations in areas of unmet…
Double-Exposed CLL/SLL: A Canadian Perspective
In this episode with Dr Robert Puckrin, we discuss the unmet needs of double-exposed patients with CLL/SLL, as well as the current and novel treatments that can address this gap. Our guestDr. Puckrin…
Thoracic Surgery Series: Resection after Neoadjuvant Immunotherapy
In this podcast episode, Dr. Dimitrios Coutsinos describes a video capsule series involving three educational videos of lung resections using minimally invasive video-assisted thoracic surgery (VATS)…
Highlights from EHA/ICML 2025: International Perspective on CLL
In this podcast episode, we discuss clinical trial updates in chronic lymphocytic leukemia from the 2025 European Hematology Association annual congress in Milan, Italy and the 18th International…
Prise en charge de la PN associée au BV utilisé pour le traitement de première intention du cH
(FRENCH) In this podcast episode, which follows this introduction in French, Dr Christopher Lemieux summarizes a paper by Dr Abramson, et al. on the management of Peripheral Neuropathy Associated…
Management of Peripheral Neuropathy Associated with Brentuximab Vedotin in cHL
In this podcast episode, Dr. Michael Chu discusses the management of peripheral neuropathy associated with the use of brentuximab vedotin for the first-line treatment of classical Hodgkin Lymphoma.…
ASH 2024: Updates on CLL
In this podcast episode, Dr. Versha Banerji, a Canadian hematologist from Manitoba and Dr. Jennifer Brown, an internationally renowned hematologist from the United States, discuss data on the…
Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape
In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL. Our Guest:Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba…
Highlights from EHA 2024 - Updates on the Treatment of CLL
In this podcast episode, three of Canada’s top hematologists discuss data on the treatment of CLL presented at the European Hematology Association (or EHA) meeting in Madrid, Spain. The discussion…
LIVE FROM EHA 2024 - Sonrotoclax plus Zanubrutinib in R/R CLL
In this episode of our podcast, recorded at the European Hematology Association (EHA) meeting in Madrid, Spain, we discuss updated results of the BGB-11417-101 trial with Dr. Stephen Opat. The…
Cutting Edge Advances in the Treatment of Lung Cancer
In this episode, Dr. Barbara Melosky discusses cutting edge approaches to the treatment of Lung Cancer, including the use of artificial intelligence and novel therapeutic approaches such as cancer…
Precision Medicine Series: Ep15: Biomarkers in Upper GI Cancers
Welcome to our podcast episode on diagnostic, prognostic and predictive biomarkers for the treatment of upper GI cancers. In this episode, Dr Brezden-Masley (medical oncologist) and Dr Streutker…
Management of Cutaneous Squamous Cell Carcinoma (cSCC): A Surgeon’s Perspective
In this video capsule, Dr. Mark Taylor discusses the surgical implications for the treatment of cSCC. This podcast episode is best viewed alongside the slides, which can be found in the video capsule…
Immunotherapy for Kidney Transplant Patients with Skin Cancer
In this podcast episode, Dr. Evan Lipson discusses the use of immunotherapy for patients with skin cancer who have had a kidney transplant. Our guest:Dr. Lipson is an internationally-recognized skin…
LIVE FROM ASH 2023: Isa-CYBORD induction chemotherapy in newly diagnosed, transplant eligible MM
In this podcast episode, Dr. Rami Kotb and Dr. Donna Reece discuss results of the CMRG Isa-CYBORD trial presented at the ASH 2023 meeting, and the implications of the results for Canadian clinical…
Live from ASH 2023: Dr Brown Discusses Updated Results of the ALPINE Trial in CLL
In this episode of our podcast, recorded at the American Society of Hematology (ASH) in San Diego, California, we discuss updated results of the ALPINE trial with Dr. Jennifer Brown. The ALPINE…
S2E5 First-line treatment strategies for the management of la/mUC: S2 Ep 5 - ESMO 2023: Discussion on 1L LA/mUC
In this video capsule series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada.This fifth episode of the series was…
First Line la/mUC Evolving Treatment Strategies: S2 Ep 3 - Case Discussion
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a…
S2E1 First Line la/mUC Evolving Treatment Strategies: S2 Ep 1 - Unmet Needs
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a…
First Line la/mUC Evolving Treatment Strategies: S2 Ep 2 - First-Line Treatment
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a…
Frequently Asked Questions
IMPACT Medicom has published 56 episodes since October 2020, covering topics in Science.
IMPACT Medicom is currently highly active with new episodes every 2 months. Average episode length is 23m.
Sign up on Grep.FM to access contact details for IMPACT Medicom, including email and social media links.
